Biotech Stocks Facing FDA Decision In May 2022

The FDA decision on Amicus Therapeutics' (FOLD) New Drug Application for Miglustat, one of the two components of AT-GAA, proposed for adult patients with Pompe disease, is slated for May 29.

from RTT - Top Story https://ift.tt/2u7ITqM
via IFTTT